Danaher Corp (NYSE:DHR) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the consensus of $5.59 billion. Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year in the first quarter.Danaher reported second-quarter adjusted EPS of $1.88, down from $1.92 a year ago, beating the consensus of $1.64.Also Read: Danaher Pricing Strategy Key To Navigating Tariff Challenges: AnalystStifel on Tuesday wrote, "DHR's start to the year was solid, as the company posted a beat and gave positive commentary around arguably the two most trending topics: ...Full story available on Benzinga.com
Danaher is a Washington-based medical device company that manufactures and supplies testing instruments and diagnostic equipment for the healthcare industry across the globe.